What did @drmakkani actually say?
Dr. Makkani's core argument is simple: compounded GLP-1s are not FDA-approved, dosing depends on syringes and math instead of pre-set amounts, and that variability creates real patient risk. She says people are told compounded versions are "the same thing just cheaper" but claims that's not true. She's not wrong to raise these concerns, but the picture is more complicated than her video suggests.
She specifically flags inconsistent active ingredients, added or different formulations, and the downstream consequences of dosing errors, including nausea, vomiting, dehydration, and ER visits. Her conclusion is personal: she won't prescribe compounded GLP-1s and sticks with FDA-approved medications where she knows what's in the pen or vial.
Does the science back this up?
Mostly yes, with some important caveats. The FDA has issued multiple safety communications about compounded semaglutide and tirzepatide, including warnings about incorrect dosing, poor labeling, and the use of salt forms like semaglutide sodium that differ from the base compound used in Ozempic and Wegovy. Those are real, documented problems, not hypothetical ones.
A 2023 report from the National Academies of Sciences, Engineering, and Medicine confirmed that compounded drugs lack the manufacturing consistency required of FDA-approved products. The FDA's own MedWatch database has logged adverse event reports tied to compounded GLP-1s, including hospitalizations. Guerrero et al. (2024, JAMA) documented cases of patients receiving ten times the intended dose due to unit confusion on syringes. The risk Dr. Makkani describes is not theoretical. It has happened to real patients.
That said, no large-scale comparative trial has directly measured outcomes between compounded and brand-name GLP-1s in equivalent patient populations, so blanket safety claims in either direction should be held carefully.
What did they get wrong (or right)?
She gets the regulatory status right. Compounded GLP-1s are not FDA-approved, full stop. Saying they're "not the same thing just cheaper" is also defensible, particularly given the salt-form issue and variable compounding quality across different pharmacies. She's right that dosing errors with GLP-1s can have real consequences.
Where she oversimplifies: compounding pharmacies are not unregulated. 503A and 503B compounders operate under state board oversight and USP standards, and 503B outsourcing facilities face more stringent federal inspection requirements. Her framing implies compounded drugs exist in a lawless void, and that's not accurate. Variability exists on a spectrum, and a well-run 503B facility is not the same as a random online pharmacy shipping unlabeled vials.
She also doesn't mention that the FDA explicitly authorized compounding of semaglutide and tirzepatide during shortage periods, which somewhat complicates the narrative that accessing them through compounders is straightforwardly irresponsible. That authorization has since been contested and partially reversed, but the history matters for patient trust.
What should you actually know?
If you're considering any GLP-1 therapy, the source and quality of the compound matters enormously. Not all compounders are equal. The FDA has specifically flagged products using semaglutide sodium or acetate salt forms, which are chemically distinct from the active ingredient in approved products, and those distinctions are not minor. Patients should ask their prescribers directly whether the pharmacy is a 503A or 503B facility, and whether the formulation uses base semaglutide or a salt form.
The side effects Dr. Makkani describes, nausea, vomiting, dehydration, are real and dose-dependent. They occur with approved GLP-1s too, but the risk of accidental overdose is higher when a patient is drawing from a vial with a syringe versus clicking a pen to a preset dose. That's a legitimate safety point worth taking seriously.
- Ask your provider which compounding pharmacy they use and whether it's FDA-registered under 503B.
- Avoid any product labeled with a salt form of semaglutide or tirzepatide.
- Do not adjust your own dose without provider guidance, regardless of the product source.
- Check the FDA's list of compounders under enforcement action before filling any prescription.